Circio Holding ASA (0RIS.L)

11.20 +0.08 (+0.69%) At close: 04:10PM BST

Circio Holding ASA

St. Olavs Plass 5
Oslo 0165
Norway
47 92 95 17 88
https://www.circio.com

Sector(s): 
Industry: 
Full-time employees: 9

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Erik Digman Wiklund	Chief Executive Officer	2.6M	N/A	N/A
Dr. Lubor Gaal Ph.D.	CFO & Head of BD	2.88M	N/A	1968
Mr. Ola Melin	Chief Operating Officer	1.97M	N/A	N/A
Dr. Thomas Birkballe Hansen	Chief Technology Officer	1.97M	N/A	N/A
Dr. Victor Levitsky M.D., Ph.D.	Chief Scientific Officer	790k	N/A	N/A
Mr. Jon Amund Eriksen M.Sc., MSc	Special Advisor	1.86M	N/A	N/A
Prof. Gustav Gaudernack Ph.D.	Chief Scientific Adviser	N/A	N/A	N/A
Dr. Peter Skorpil Ph.D.	Vice President of Business Development	1.07M	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in NOK.

Description

Circio Holding ASA, a biotechnology company, develops novel circular RNA and immunotherapy medicines. The company is developing TG01, a cancer vaccine targeting driver mutations, which is in three clinical trials for multiple myeloma, and pancreatic and lung cancer; and circVec circRNA vector platform, a modular genetic cassette for biogenesis of multifunctional circRNAs in human cells. The company was formerly known as Targovax ASA and changed its name to Circio Holding ASA in May 2023. The company was incorporated in 2010 and is based in Oslo, Norway.

Corporate governance

Circio Holding ASA’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.